The possible efficacy of a reduced number of DCS administrations can be explained by the progressive desensitization of receptors with continued use of the substance. This finding is supported by the meta-analysis of Norberg et al. on the use of DCS in animals and humans, in which the rapid development of tolerance is shown. It was also found in that meta-analysis that time of administration of DCS was a predictor of effect size, and the best effects were obtained when the substance was administered Moexipril HCl immediately before or soon after exposure. Other studies with animal models also support this finding, suggesting that the effects of augmentation with DCS occur during the period of memory consolidation that occurs after exposure rather than during exposure Taurocholic Acid sodium hydrate itself. In OCD, where the lack of standardization was higher, the results for enhancement with DCS were less promising. A difference between intervention and placebo groups was found when the drug was administered 1 to 2 hours before exposure sessions, but not when administered 4 hours before, which may also have contributed to the negative results, since DCS seems to be more effective when used shortly before the exposure sessions. Also, these findings are in accordance with studies with animal models, reinforcing the idea that DCS is effective when administered immediately before or soon after exposure. In this study by Storch et al., DCS was administered at a dose of 250 mg four hours before the session and for a long period of time. The studies that showed positive results used brief protocols. Studies conducted by Wilhelm et al. and Kushner et al., who used twice-weekly sessions, found significantly higher results in the DCS group at the fifth and fourth sessions, respectively, but this effect was not observed at the end of 10 sessions. In a additional article, Chasson et. al. re-analyzed data from the study by Wilhelm et al. and the outcomes indicated that the group that received DCS achieved results 2.3 times faster than the placebo group and six times faster in the first half of the sessions of exposure therapy, suggesting that DCS accelerates the gains of exposure in OCD. These data indicate that the effects of DCS are concentrated in the first sessions of exposure.